<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104480</url>
  </required_header>
  <id_info>
    <org_study_id>RP2010</org_study_id>
    <nct_id>NCT01104480</nct_id>
  </id_info>
  <brief_title>Tocilizumab for Relapsing Polychondritis</brief_title>
  <official_title>Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study for one patient with severe relapsing polychondritis which has been
      unresponsive to other more conventional medications including prednisone, methotrexate,
      anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be
      monitored by clinical assessment and bloodwork.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Tocilizumab was licenced in Canada for children, so the study was not necessary
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Tocilizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Inhibition of inflammatory markers Improvement in symptoms and signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Tocilizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Monitoring of serum lipids and liver function tests</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsing Polychondritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 8mg/kg every 2 weeks given by IV infusion</description>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A single patient with unremitting inflammatory relapsing polychondritis

        Exclusion Criteria:

          -  As this is a study in a single patient, there are no exclusions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Larch√©, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3YZ</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster Children's Hospital</investigator_affiliation>
    <investigator_full_name>Dr Maggie Larche</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Relapsing Polychondritis</keyword>
  <keyword>Unremitting</keyword>
  <keyword>Inflammation</keyword>
  <keyword>IL6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polychondritis, Relapsing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

